MedTrace Logo

Screening for Amyloidosis Before Aortic Valve Elective Replacement

NCT04869631 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-02-12

No results posted yet for this study

Summary

Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).

Conditions

  • Amyloidosis
  • Aortic Valve Stenosis

Interventions

OTHER

The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.

We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.

Sponsors & Collaborators

  • Deutsches Herzzentrum Berlin, Klinik für Innere Medizin - Kardiologie

    collaborator UNKNOWN

  • Klinik für Neurologie mit Experimenteller Neurologie, Charité - Universitätsmedizin Berlin

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-03-31
Completion
2028-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869631 on ClinicalTrials.gov